公开(公告)号：US20170360763A1

公开(公告)日：2017-12-21

申请号：US15585038

申请日：2017-05-02

Applicant: Infinity Pharmaceuticals, Inc.

Inventor： Alfredo C. Castro ,  Michael J. Grogan ,  Karen J. McGovern ,  Martin R. Tremblay

IPC: A61K31/4355 ,  A61K9/00 ,  C07D491/10 ,  C07D491/048 ,  C07D491/04 ,  C07D471/10 ,  C07D471/04 ,  C07D307/94 ,  A61N5/10 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/69 ,  A61K31/664 ,  A61K31/58 ,  A61K31/573 ,  A61K31/56 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/454 ,  A61K31/198 ,  A61K31/196 ,  A61K31/17 ,  C07D491/107 ,  C07J69/00

CPC classification number: A61K31/4355 ,  A61K9/0014 ,  A61K31/17 ,  A61K31/196 ,  A61K31/198 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/519 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/664 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K45/06 ,  A61N5/10 ,  C07D307/94 ,  C07D471/04 ,  C07D471/10 ,  C07D491/04 ,  C07D491/048 ,  C07D491/10 ,  C07D491/107 ,  C07J69/00

Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:

公开(公告)号：US20170354624A1

公开(公告)日：2017-12-14

申请号：US15687607

申请日：2017-08-28

Applicant: RESDEVCO RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Shabtay DIKSTEIN

IPC: A61K31/196 ,  A61K47/24 ,  A61K8/44 ,  A61K47/14 ,  A61K9/00 ,  A61K8/55 ,  A61K8/86 ,  A61K47/26 ,  A61K47/18 ,  A61K8/42 ,  A61Q19/00 ,  A61K8/19 ,  A61K8/37 ,  A61K47/32 ,  A61K8/81 ,  A61K47/10 ,  A61K8/04 ,  A61K8/34 ,  A61K47/02 ,  A61K9/06 ,  A61K8/41

CPC classification number: A61K31/196 ,  A61K8/042 ,  A61K8/19 ,  A61K8/345 ,  A61K8/37 ,  A61K8/41 ,  A61K8/42 ,  A61K8/44 ,  A61K8/553 ,  A61K8/8141 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/06 ,  A61K31/047 ,  A61K31/17 ,  A61K31/198 ,  A61K31/7004 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/183 ,  A61K47/24 ,  A61K47/26 ,  A61K47/32 ,  A61K2800/30 ,  A61K2800/5922 ,  A61K2800/75 ,  A61Q19/00 ,  A61Q19/005 ,  A61K2300/00

Abstract: A topical pharmaceutical or composition for prevention and treatment of irritation to skin cells. The composition comprises an aqueous solution of xylitol and glycerol. In a preferred embodiment, the composition comprises 5% (w/w) xylitol, 5% (w/w) glycerol, a viscosity-enhancing agent, base to bring to the pH to 4.9, and optionally, a pharmaceutically active agent.

公开(公告)号：US09840550B2

公开(公告)日：2017-12-12

申请号：US14429199

申请日：2013-10-01

Applicant: GENEURO SA

Inventor： Hervé Perron ,  Reza Firouzi ,  Patrick Küry ,  Raphaël Faucard ,  Alexandra Madeira ,  Julie Joanou

IPC: A61K39/42 ,  A61K31/17 ,  A61K31/194 ,  C07K16/10 ,  A61K45/06 ,  A61K31/155 ,  A61K31/223 ,  A61K31/225 ,  A61K31/221 ,  A61K39/00

CPC classification number: C07K16/1036 ,  A61K31/155 ,  A61K31/17 ,  A61K31/194 ,  A61K31/221 ,  A61K31/223 ,  A61K31/225 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

公开(公告)号：US20170333340A1

公开(公告)日：2017-11-23

申请号：US15425874

申请日：2017-02-06

Applicant: Biogen Chesapeake LLC

Inventor： Sven Martin Jacobson

IPC: A61K9/00 ,  A61K31/17 ,  A61K31/18 ,  A61K31/64

CPC classification number: A61K9/0019 ,  A61K31/17 ,  A61K31/18 ,  A61K31/64

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

公开(公告)号：US09821019B2

公开(公告)日：2017-11-21

申请号：US15005410

申请日：2016-01-25

Applicant: Princeton Biotechnology Corporation

Inventor： Frank DeMuro

IPC: A61K36/00 ,  A61K36/28 ,  A61K33/38 ,  A61K36/185 ,  A61K33/04 ,  A61K36/38 ,  A61K9/00 ,  A61K35/74 ,  A61K36/31 ,  A61K31/17 ,  A61K41/00

CPC classification number: A61K36/28 ,  A61K9/0014 ,  A61K31/17 ,  A61K33/04 ,  A61K33/38 ,  A61K35/74 ,  A61K36/185 ,  A61K36/31 ,  A61K36/38 ,  A61K41/0004 ,  A61K2300/00

Abstract: The present invention relates to a homeopathic formulation comprising dilutions of Arnica, Calendula, Echinacea, Hypericum, Silver, Sulfur, Thiosinaminum, Urtica, and methods for treating pain, inflammation, scar tissue, itching/pruritus and infection using same.

公开(公告)号：US09790169B2

公开(公告)日：2017-10-17

申请号：US15088211

申请日：2016-04-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: C07C229/42 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/395 ,  C07C255/58 ,  C07C275/40 ,  C07D205/04 ,  C07D211/14 ,  C07D239/47 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D309/04 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D309/14 ,  C07D407/12 ,  C07D487/08 ,  C07D265/30 ,  C07D207/08 ,  C07D211/08 ,  C07D307/22 ,  C07C255/57 ,  C07C235/38 ,  C07C235/56

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20170252368A1

公开(公告)日：2017-09-07

申请号：US15599617

申请日：2017-05-19

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Anthony James Lepine ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: A61K33/00 ,  A61K31/17 ,  A61K31/4709 ,  A61K9/00 ,  A61K31/519 ,  A61K9/08 ,  C01B21/50 ,  A61K31/4418

CPC classification number: A61K33/00 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/17 ,  A61K31/4418 ,  A61K31/4709 ,  A61K31/519 ,  C01B21/50 ,  Y02A50/411 ,  Y10T436/204998

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

公开(公告)号：US20170246168A1

公开(公告)日：2017-08-31

申请号：US15587928

申请日：2017-05-05

Applicant: MINERVA BIOTECHNOLOGIES CORPORATION

Inventor： Cynthia BAMDAD

IPC: A61K31/517

CPC classification number: A61K31/517 ,  A61K31/17 ,  A61K31/401 ,  A61K31/403 ,  A61K31/475 ,  A61K31/55

Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.

公开(公告)号：US20170231999A1

公开(公告)日：2017-08-17

申请号：US15584818

申请日：2017-05-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: A61K31/538 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20170216274A1

公开(公告)日：2017-08-03

申请号：US15493421

申请日：2017-04-21

Applicant: FibroGen, Inc.

Inventor： Stephen J. Klaus ,  Christopher J. Molineaux ,  Thomas B. Neff ,  Volkmar Guenzler-Pukall ,  Robert C. Stephenson ,  Todd W. Seeley ,  Ingrid Langsetmo Parobok

IPC: A61K31/472

CPC classification number: C07D217/24 ,  A61K31/00 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/472 ,  C07C275/40

Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.